Skip to Main Content

Paper Details

Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials.
Eur Urol Oncol
13
2020
Author NameAffiliation
Gregory R PondMcMaster University
Johann S de BonoInstitute of Cancer Research and The Royal Marsden Hospital
Howard I ScherMemorial Sloan Kettering Cancer Center
  • 1 - 3

Datasets

Release 1.2